Cytovir® CMV

Cytovir CMV is a personalized cellular immunotherapy comprised of donor-derived (allogeneic), naturally occurring CMV (cytomegalovirus)-specific
T cells. It is manufactured for an individual patient from a healthy donor through direct selection with MHC class I multimers using, the Streptamer® technology. Cytovir CMV has been developed for prophylaxis and treatment of CMV infections following allogeneic hematopoietic stem cell transplantation (allo-HSCT).

The donor-derived anti-CMV lymphocytes for Cytovir CMV are manufactured from peripheral blood mononuclear cells (PBMCs) of a matched donor, but can also be obtained from a family or third party donor.

The safety and clinical efficacy of Cytovir CMV have been studied in two randomized, controlled clinical trials, ASPECT and IMPACT. Cytovir CMV is now commercially available in selected countries in Europe.


Cell Medica has sponsored two randomized controlled clinical trials (ASPECT / IMPACT) assessing safety and efficacy of Cytovir CMV in allogeneic transplant patients.  These trials are now complete.